NASDAQ:HPTX - Horizon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$45.99
Today's RangeN/A
52-Week Range$20.23 - $46.96
VolumeN/A
Average Volume786,899 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive HPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HPTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:HPTX
CUSIP44915N10
WebN/A
Phone+1-650-7457802

Debt

Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A

Profitability

Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
OptionableNot Optionable

Horizon Therapeutics (NASDAQ:HPTX) Frequently Asked Questions

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HPTX."

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics Inc (NASDAQ:HPTX) announced its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.67. The biopharmaceutical company earned $30.80 million during the quarter, compared to analysts' expectations of $24.60 million. Horizon Therapeutics's quarterly revenue was up 65.6% on a year-over-year basis. View Horizon Therapeutics' Earnings History.

Has Horizon Therapeutics been receiving favorable news coverage?

Media coverage about HPTX stock has been trending negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Horizon Therapeutics earned a news impact score of -2.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Horizon Therapeutics?

Shares of HPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 2000 Sierra Point Pkwy Ste 400, BRISBANE, CA 94005-1849, United States. The biopharmaceutical company can be reached via phone at +1-650-7457802.


MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HPTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  253
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel